Beta Bionics is getting ready to enter the tubeless insulin pump market with Mint, a new patch pump designed to bring the company’s iLet automated insulin delivery technology to a smaller, wearable form factor. The company received FDA clearance for Mint and is now targeting a launch in the first quarter of 2027.

Mint uses a two-part design that consists of two parts: a small, L-shaped reusable “brain” component, and a disposable pod containing a 200-unit insulin reservoir and batteries. Unlike other upcoming tubeless pump designs like MiniMed Fit and Tubeless Mobi, Mint doesn’t need to be charged; the batteries are included in each disposable pod. The company says the pump is approved for three days of use, with a 12-hour grace period, and is IPX8 rated for activities such as swimming and showering.

Mint represents a larger expansion of the iLet ecosystem. Beta Bionics is also working on a next-generation 3D Intelligence algorithm, which introduces three new settings experiences designed to give users and healthcare providers more control over how the system balances glucose levels and hypoglycemia.

We spoke with Beta Bionics Chief Product Officer Mike Mensinger for an in-depth look at the new Mint pump, including its design, site-change process, app experience, and what’s next for the iLet algorithm. Justin and our producer recorded a post show reaction video where they broke down their feelings about the pump and what questions are still unanswered about the new algorithm.

All Access members can watch the podcast ad-free at the bottom of this page. In addition, members get early access to content, Justin’s exclusive industry analysis posts, our live event archive, and member-only giveaways.